Privately held biomedical company advances proprietary RNA intelligence platform designed to characterize Long Covid as a multi-system condition rather than a single-pathway disease

CORALVILLE, IA / ACCESS Newswire / April 29, 2026 / FBB Biomed, a privately held biomedical company developing a systems biology-based RNA intelligence platform, announced today that it has submitted its first scientific manuscript for peer-reviewed publication. The manuscript, titled "Multi-biosystem dysregulation in neurologic post-acute sequelae of SARS-CoV-2 infection (PASC)," describes the company's proprietary approach to characterizing patients with PASC (long COVID) through a coordinated, multi-system molecular framework rather than the single-pathway approach that has defined most prior efforts in the field is currently under journal peer review.

Long COVID, formally known as post-acute sequelae of SARS-CoV-2 infection, or PASC, affects an estimated 10-30% of individuals following acute COVID-19 infection. Among its most disabling features are persistent neurologic symptoms, including cognitive impairment, dysautonomia, fatigue, and impaired executive function. Despite significant global research, PASC remains difficult to characterize using a single reproducible blood-based molecular approach, with most efforts focused on individual pathways such as inflammation, vascular injury, or autoimmunity rather than a coordinated, multi-system view. Once validated, this approach could help researchers better stratify patients, design studies and monitor treatment response in complex chronic conditions.

"Long COVID is far more complicated than a single-pathway disease," said Howard Urnovitz, PhD, Co-Founder and CEO of FBB Biomed. "Our platform was built on the premise that complex chronic conditions like PASC reflect coordinated dysregulation across multiple interacting biological systems simultaneously. The manuscript we have submitted describes that framework formally for the first time."

About the platform

FBB Biomed's RNA intelligence platform combines proprietary RNA enrichment chemistry with a nine-system biological ontology to enable simultaneous assessment of multiple physiological systems from a single blood draw. The architecture is designed to support patient stratification, clinical trial design, and longitudinal therapy monitoring across diseases where multi-system pathology has historically defied single-biomarker approaches.

"We are submitting this manuscript so that the scientific community and peer reviewers can evaluate the framework on its merits," added Urnovitz. "The underlying data and details will be made available once the manuscript is accepted for publication in a peer-reviewed journal."

About FBB Biomed

FBB Biomed is a privately held biomedical company headquartered in Coralville, Iowa, developing systems-biology-based RNA intelligence platforms for complex chronic diseases. The company's approach, proprietary RNA enrichment combined with a nine-system biological ontology, is designed to address conditions where single-biomarker approaches have historically struggled. Application areas under active development include Neurologic Disease and Disorders, including neurologic long COVID.

For more information, visit FBBbio.com or contact:

Media Contact: Howard Urnovitz, CEO, FBB Biomed, howard@fbbbio.com

This press release does not disclose specific scientific findings from the submitted manuscript, which is currently under peer review. Detailed methods, results, and conclusions will be made available through formal scientific publication. Statements regarding potential platform applications are forward-looking and depend on future research, regulatory pathways, and other factors; actual outcomes may differ materially.

SOURCE: FBB Biomed